Physician profile
Manuel Alejandro Padilla
NPI 1164440400
$21,460.09
in general payments reported to CMS, 2019-2025
50 companies · $2,361 in 2025
The $2,361 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,236 · 2020: $2,547 · 2021: $4,113 · 2022: $3,459 · 2023: $3,285 · 2024: $2,460 · 2025: $2,361.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,089 · Education: $16.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,089.47 |
| Education | $16.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $5,709.42 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $2,013.33 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $1,839.96 | 2019-2025 | |
| Abbott Laboratories | $1,290.08 | 2020-2025 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $1,038.78 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $917.33 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $856.41 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Amgen INC. | $804.08 | 2019-2025 | Repatha, Otezla, Otezla |
| Janssen Pharmaceuticals, INC | $692.59 | 2019-2024 | Spravato |
| Allergan, INC. | $665.26 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $547.09 | 2021-2025 | |
| Pfizer INC. | $537.28 | 2019-2025 | |
| Amarin Pharma, INC. | $410.33 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $396.90 | 2019-2024 | Trintellix |
| Biohaven Pharmaceuticals, INC. | $329.44 | 2020-2021 |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manuel Padilla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.